Search

Displaying results 1971 - 1980 of 6949 in total
  1. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    [A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such

    Categories: Antihypertensive Agents Indicated for Hypertension, Adrenergic beta-1 Receptor Antagonists
  2. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.

  3. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.

  4. Drug

    Ketotifen

    go.drugbank.com/drugs/DB00920
    ApprovedInvestigational

    available and indicated as an add-on therapy for children with atopic asthma. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.

    Categories: Antihistamines for Systemic Use
  5. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    /CD3 bispecific monoclonal antibody approved for DLBCL. … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  6. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  7. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru).

    Mixtures: OMEGA PLUS EMULSION FOR INFUSION, OMEGA SPECIAL EMULSION FOR INFUSION
  8. Drug

    Naphazoline

    go.drugbank.com/drugs/DB06711
    Approved

    Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].

    Mixtures: Visine for Allergy With Antihistamine, Clear Eyes for Dry Eyes Plus Redness ReliefCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  9. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … [L4168] It was approved for the same indications in Canada in June 2022.

    Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 Interactions
  10. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

    Categories: Angiotensin 2 Receptor Blocker, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)